Hot Features
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatolog... MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.87 | -4.63505594033 | 18.77 | 19.6 | 17.66 | 791033 | 18.56520117 | CS |
| 4 | 0.53 | 3.05123776626 | 17.37 | 21 | 15.76 | 973349 | 18.14702316 | CS |
| 12 | 0.76 | 4.43407234539 | 17.14 | 21 | 15.76 | 1001731 | 17.66571357 | CS |
| 26 | 2.77 | 18.3079973562 | 15.13 | 21 | 11.06 | 1543735 | 16.38269292 | CS |
| 52 | -32.41 | -64.4205923276 | 50.31 | 62.75 | 5.95 | 2175100 | 14.99620757 | CS |
| 156 | -9.54 | -34.7667638484 | 27.44 | 64.98 | 5.95 | 1041149 | 24.90941881 | CS |
| 260 | 5.53 | 44.7049312854 | 12.37 | 64.98 | 4.25 | 794215 | 24.46800693 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.